$TEVA Turnaround may have begun in Teva Pharmaceutical.
Revenues: $4,264M (-5.9%).
Key product sales: Copaxone: $397M (-33.9%); Generics: $2,224B (-1.8%).
Net loss: ($314M) (-15.0%); non-GAAP net income: $637M (-8.2%); loss/share: ($0.29) (-7.4%); non-GAAP EPS: $0.58 (-14.7%).
Cash flow ops: $325M (-22.8%).
2019 guidance: Revenues: $17.2B - 17.4B from $17.0B - 17.4B; operating income: $4.0B - 4.2B from $3.8B - 4.2B; EBITDA: $4.5B - 4.8B from $4.4B - 4.8B; EPS: $2.30 - 2.50 from $2.20 - 2.50; free cash flow: $1.7B - 2.0B from $1.6B - 2.0B.
Eli Kalif appointed EVP and Chief Financial Officer effective December 22. He joins the firm from Flex Ltd where he was SVP Finance Global Operations, Components & Services.
Shares up 4% premarket on increased .
Previously: Teva Pharmaceutical EPS misses by $0.01, beats on revenue (Nov. 7)
Source Seeking Alpha
Short interest relatively high at 7%
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines . The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines . The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
1) Sign Up for our Free Email Newsletter @
2) Sign Up for our Free Text Message Notifications
by Texting 'GAINS' to 67076.
(*It's FREE, however Msg&Data rates may apply